S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
5 Short Squeeze Candidates With Catalysts For Rebounds

Cytokinetics (CYTK) Stock Forecast, Price & News

$26.88
-1.00 (-3.59%)
(As of 10/3/2023 ET)
Compare
Today's Range
$26.57
$28.12
50-Day Range
$26.88
$36.61
52-Week Range
$26.57
$52.40
Volume
1.39 million shs
Average Volume
956,407 shs
Market Capitalization
$2.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.21

Cytokinetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
116.6% Upside
$58.21 Price Target
Short Interest
Bearish
13.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
0.26mentions of Cytokinetics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.55 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.10) to ($3.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

416th out of 966 stocks

Pharmaceutical Preparations Industry

179th out of 442 stocks


CYTK stock logo

About Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Price History

CYTK Stock News Headlines

Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Cytokinetics: Clinical Efficacy Isn't Enough For Success
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
Mizuho Securities Sticks to Its Buy Rating for Cytokinetics (CYTK)
Cytokinetics (CYTK) Receives a Buy from Mizuho Securities
Aficamten Sets Cytokinetics Apart In Cardiomyopathy
Piper Sandler Remains a Buy on Cytokinetics (CYTK)
H.C. Wainwright Keeps Their Buy Rating on Cytokinetics (CYTK)
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Company Calendar

Last Earnings
8/03/2023
Today
10/04/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
409
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$58.21
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+116.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Net Income
$-388,950,000.00
Net Margins
-5,419.17%
Pretax Margin
-5,422.19%

Debt

Sales & Book Value

Annual Sales
$94.59 million
Book Value
($1.14) per share

Miscellaneous

Free Float
92,350,000
Market Cap
$2.58 billion
Optionable
Optionable
Beta
0.80

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Robert I. BlumMr. Robert I. Blum (Age 59)
    CEO, Pres & Director
    Comp: $1.14M
  • Mr. Ching W. JawMr. Ching W. Jaw (Age 60)
    Sr. VP & CFO
    Comp: $698.49k
  • Mr. Robert C. Wong (Age 55)
    VP & Chief Accounting Officer
    Comp: $463.75k
  • Dr. Fady Ibraham Malik FACC (Age 59)
    M.D., Ph.D., Exec. VP of R&D
    Comp: $776.99k
  • Mr. Andrew M. Callos (Age 67)
    Exec. VP & Chief Commercial Officer
    Comp: $745.4k
  • Dr. James A. Spudich Ph.D. (Age 81)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Jeff Lotz
    VP of Sales & Operations
  • Mr. Steven M. Cook (Age 64)
    Sr. VP of Supply Chain Operations & Technical Operations
  • Ms. Diane Weiser
    Sr. VP of Corp. Communications & Investor Relations
  • Ms. Kari K. Loeser J.D.
    VP & Chief Compliance Officer













CYTK Stock - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price forecast for 2023?

14 brokerages have issued twelve-month target prices for Cytokinetics' shares. Their CYTK share price forecasts range from $42.00 to $80.00. On average, they anticipate the company's stock price to reach $58.21 in the next year. This suggests a possible upside of 116.6% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2023?

Cytokinetics' stock was trading at $45.82 on January 1st, 2023. Since then, CYTK stock has decreased by 41.3% and is now trading at $26.88.
View the best growth stocks for 2023 here
.

Are investors shorting Cytokinetics?

Cytokinetics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 12,550,000 shares, an increase of 8.1% from the August 31st total of 11,610,000 shares. Based on an average daily volume of 799,100 shares, the days-to-cover ratio is presently 15.7 days. Currently, 13.7% of the company's stock are short sold.
View Cytokinetics' Short Interest
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.11. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $5.67 million. Cytokinetics's revenue was down 99.0% on a year-over-year basis. During the same period last year, the company posted ($0.23) EPS.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $26.88.

How much money does Cytokinetics make?

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $2.58 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis.

How many employees does Cytokinetics have?

The company employs 409 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.

This page (NASDAQ:CYTK) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -